Sign In
Buy CELC
$88.95
-2.47 (-2.70%)
At Close: Jun 03, 2026
MINNEAPOLIS, March 09, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced publicatio
Celcuity Inc. (CELC) Presents at TD Cowen 46th Annual Health Care Conference Transcript
02:28pm, Monday, 09'th Mar 2026
Celcuity Inc. (CELC) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Choreo LLC Takes Position in Celcuity, Inc. $CELC
03:42am, Monday, 09'th Mar 2026
Choreo LLC purchased a new stake in shares of Celcuity, Inc. (NASDAQ: CELC) in the third quarter, according to its most recent disclosure with the SEC. The firm purchased 5,028 shares of the company's
Celcuity CEO Details Gedatolisib NDA, July PDUFA and Launch Plans at TD Cowen Conference
02:05am, Monday, 09'th Mar 2026
Celcuity (NASDAQ: CELC) CEO and co-founder Brian Sullivan outlined the company's clinical programs, regulatory progress, and commercial launch preparations for gedatolisib during a fireside chat at TD
Investment Manager Loads Up on CELC Stock, Adds 135,000 Shares, According to Latest SEC Filing
09:19am, Friday, 06'th Mar 2026
Acquired 135,000 shares of Celcuity; estimated trade size of $11.10 million based on quarterly average pricing Quarter-end position value rose by $18.00 million, reflecting both trading and price appr
Artisan International Small-Mid Fund Q4 2025 Performance Review
01:38pm, Monday, 02'nd Mar 2026
The portfolio meaningfully outperformed the MSCI EAFE Small Cap Growth Index but modestly lagged the blend MSCI ACWI ex USA SMID Index. Our portfolio, which has a structural growth orientation, has no
Celcuity To Participate in Upcoming Investor Conferences
04:01pm, Wednesday, 25'th Feb 2026
MINNEAPOLIS, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position
02:05pm, Sunday, 22'nd Feb 2026
Perceptive Advisors purchased 203,881 Celcuity shares in the fourth quarter; the estimated trade value was $16.76 million based on average fourth-quarter pricing. Meanwhile, the quarter-end position v
Celcuity, Inc. (NASDAQ:CELC) Given Average Rating of “Moderate Buy” by Brokerages
03:28am, Thursday, 19'th Feb 2026
Shares of Celcuity, Inc. (NASDAQ: CELC - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the ten brokerages that are currently covering the stock, Marketbeat.com reports.
Celcuity Inc. (CELC) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
04:17pm, Friday, 13'th Feb 2026
Celcuity Inc. (CELC) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
Has Celcuity (CELC) Outpaced Other Medical Stocks This Year?
10:40am, Friday, 13'th Feb 2026
Here is how Celcuity, Inc. (CELC) and Day One Biopharmaceuticals, Inc. (DAWN) have performed compared to their sector so far this year.
Soleus Adds a Significant Number of Celcuity Shares
07:34am, Friday, 13'th Feb 2026
Soleus increased its Celcuity stake by 629,398 shares. The firm held over 1.8 million shares at the end of the quarter.
Celcuity Appoints Charles Romp to its Board of Directors
04:05pm, Thursday, 12'th Feb 2026
MINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the appoint
AlTi Global Inc. Purchases New Shares in Celcuity, Inc. $CELC
03:52am, Thursday, 12'th Feb 2026
AlTi Global Inc. acquired a new position in shares of Celcuity, Inc. (NASDAQ: CELC) during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Ex
Celcuity, Inc. $CELC Stake Boosted by New York State Common Retirement Fund
06:14am, Monday, 09'th Feb 2026
New York State Common Retirement Fund raised its holdings in shares of Celcuity, Inc. (NASDAQ: CELC) by 68.0% in the undefined quarter, according to the company in its most recent disclosure with the
